Biogen Inc. (BIIB)
NASDAQ: BIIB · Real-Time Price · USD
126.56
-4.48 (-3.42%)
At close: Jun 17, 2025, 4:00 PM
125.49
-1.07 (-0.85%)
After-hours: Jun 17, 2025, 7:54 PM EDT
Biogen Revenue
Biogen had revenue of $2.43B in the quarter ending March 31, 2025, with 6.13% growth. This brings the company's revenue in the last twelve months to $9.82B, up 1.59% year-over-year. In the year 2024, Biogen had annual revenue of $9.68B, down -1.62%.
Revenue (ttm)
$9.82B
Revenue Growth
+1.59%
P/S Ratio
1.88
Revenue / Employee
n/a
Employees
n/a
Market Cap
18.54B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 9.68B | -159.70M | -1.62% |
Dec 31, 2023 | 9.84B | -337.80M | -3.32% |
Dec 31, 2022 | 10.17B | -808.30M | -7.36% |
Dec 31, 2021 | 10.98B | -2.46B | -18.32% |
Dec 31, 2020 | 13.44B | -933.30M | -6.49% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
BIIB News
- 5 days ago - Dapirolizumab Pegol Phase 3 Data in SLE Presented at the Annual European Congress of Rheumatology (EULAR) Show Improvement in Fatigue and Reduction in Disease Activity - GlobeNewsWire
- 7 days ago - Biogen Inc. (BIIB) Presents at Goldman Sachs 46th Annual Global Healthcare Conference (Transcript) - Seeking Alpha
- 14 days ago - Entrada Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors - GlobeNewsWire
- 21 days ago - Biogen and City Therapeutics Announce Strategic Research Collaboration to Develop Select Novel RNAi-based Therapies - GlobeNewsWire
- 5 weeks ago - Trump Declares War On Pharma Drug Pricing, But The Stocks Aren't Tanking - Yet - Seeking Alpha
- 5 weeks ago - Jeito Capital Strengthens Leadership for Next Chapter of Growth: Mehdi Ainouche Promoted to Partner, Julien Elric to Senior Principal - GlobeNewsWire
- 6 weeks ago - Biogen Inc. (BIIB) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 6 weeks ago - Biogen beats quarterly profit estimates on strong demand for rare disease drugs - Reuters